Peter Norman
Research Subjects
Research Interests
Latest Publications
- 1 April 2020
- Published by Clarivate Analytics (US) LLC in Drugs of the Future
- Vol. 45 (4) , 273-277
6th RSC/SCI Symposium on Ion Channels as Therapeutic Targets
- 1 April 2020
- Published by Clarivate Analytics (US) LLC in Drugs of the Future
- Vol. 45 (4) , 273-277
6th RSC/SCI Symposium on Ion Channels as Therapeutic Targets
- 1 January 2019
- Published by Portico in Drugs of the Future
- Vol. 44 (3) , 233-240
2nd SCI/RSC Symposium on Antimicrobial Drug Discovery. London, UK - November 12-13, 2018
- 1 January 2019
- Published by Portico in Drugs of the Future
- Vol. 44 (3) , 233-240
2nd SCI/RSC Symposium on Antimicrobial Drug Discovery. London, UK - November 12-13, 2018
- 23 September 2011
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 21 (11) , 1805-1810
Novel 1,5-naphthyridine PI3K? inhibitors, an evaluation of WO2011075628
A small series of aryl(1-arylamino)ethyl,1,5-naphthyridine derivatives that selectively inhibit PI3Kδ was prepared. The compounds are claimed to be useful in the treatment of cancer, inflammatory and autoimmune diseases. The compounds represent further variations around a structural motif explored in a number of previous applications by the applicant.
- 23 September 2011
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 21 (11) , 1805-1810
Novel 1,5-naphthyridine PI3K? inhibitors, an evaluation of WO2011075628
A small series of aryl(1-arylamino)ethyl,1,5-naphthyridine derivatives that selectively inhibit PI3Kδ was prepared. The compounds are claimed to be useful in the treatment of cancer, inflammatory and autoimmune diseases. The compounds represent further variations around a structural motif explored in a number of previous applications by the applicant.
- 22 September 2011
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 21 (12) , 1919-1924
A dual CCR2/CCR5 chemokine antagonist, BMS-813160?
(2011). A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Expert Opinion on Therapeutic Patents: Vol. 21, No. 12, pp. 1919-1924. doi: 10.1517/13543776.2011.622750
- 22 September 2011
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 21 (12) , 1919-1924
A dual CCR2/CCR5 chemokine antagonist, BMS-813160?
(2011). A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Expert Opinion on Therapeutic Patents: Vol. 21, No. 12, pp. 1919-1924. doi: 10.1517/13543776.2011.622750
- 9 May 2011
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 21 (7) , 1137-1142
Boehringer Ingleheim's selective glucocorticoid receptor agonist development candidate: evaluation of WO2010141331, WO2010141332 and WO2010141333
Three applications from Boehringer Ingelheim all relate to the preparation of non-steroidal glucocorticoid receptor agonists useful in the treatment of inflammatory respiratory diseases. The first two applications claim chiral processes for the preparation of these compounds or intermediates useful therein. These provide two alternative routes, respectively, using achiral and chiral reagents. The third application relates to the preparation of a crystalline salt of the preferred compound on a multi-kilogram scale in micronised form.
- 9 May 2011
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 21 (7) , 1137-1142
Boehringer Ingleheim's selective glucocorticoid receptor agonist development candidate: evaluation of WO2010141331, WO2010141332 and WO2010141333
Three applications from Boehringer Ingelheim all relate to the preparation of non-steroidal glucocorticoid receptor agonists useful in the treatment of inflammatory respiratory diseases. The first two applications claim chiral processes for the preparation of these compounds or intermediates useful therein. These provide two alternative routes, respectively, using achiral and chiral reagents. The third application relates to the preparation of a crystalline salt of the preferred compound on a multi-kilogram scale in micronised form.
- 23 February 2011
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 21 (3) , 425-429
New H1/H3antagonists for treating allergic rhinitis: WO2010094643
This application claims dual receptor specificity antihistamines, active as H(1) and H(3) antagonists, which additionally have a long duration of action that renders them suitable for once daily administration via inhalation for the treatment of allergic rhinitis. The compounds lack CNS penetration and have a high affinity for both histamine receptors.
- 23 February 2011
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 21 (3) , 425-429
New H1/H3antagonists for treating allergic rhinitis: WO2010094643
This application claims dual receptor specificity antihistamines, active as H(1) and H(3) antagonists, which additionally have a long duration of action that renders them suitable for once daily administration via inhalation for the treatment of allergic rhinitis. The compounds lack CNS penetration and have a high affinity for both histamine receptors.
- 5 January 2011
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 21 (2) , 277-280
Crystalline form of a neutrophil elastase inhibitor, 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide p-toluene sulfonate - is it AZD-9668?: WO-2010094964.
This patent application claims a novel crystalline form (Form A) of a tosylate salt of a previously disclosed neutrophil elastase inhibitor. It also claims oral compositions of the salt and a process for the preparation of the crystalline form. The novel form is indicated to show improved physical properties relative to the free base. The claimed compound is evidently one of the elastase inhibitors currently being developed by AstraZeneca.
- 5 January 2011
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 21 (2) , 277-280
Crystalline form of a neutrophil elastase inhibitor, 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide p-toluene sulfonate - is it AZD-9668?: WO-2010094964.
This patent application claims a novel crystalline form (Form A) of a tosylate salt of a previously disclosed neutrophil elastase inhibitor. It also claims oral compositions of the salt and a process for the preparation of the crystalline form. The novel form is indicated to show improved physical properties relative to the free base. The claimed compound is evidently one of the elastase inhibitors currently being developed by AstraZeneca.
- 8 July 2009
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 19 (11) , 1629-1633
AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653
The applications WO2008103126 and WO2009011653, respectively, claim: i) Combinations of a spirocyclic piperidine chemokine CCR1 antagonist with a corticosteroid, and their use for the treatment of asthma and chronic obstructive pulmonary disease. ii) Processes for the preparation of a spirocyclic piperidine derivative, a chemokine CCR1 antagonist. These applications point to the preferred compound being a development compound. The evidence for this compound being AZD-4818, a chemokine CCR1 antagonist that was in Phase II development for the treatment of chronic obstructive pulmonary disease, is reviewed in the light of these and earlier patents relating to it.
- 8 July 2009
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 19 (11) , 1629-1633
AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653
The applications WO2008103126 and WO2009011653, respectively, claim: i) Combinations of a spirocyclic piperidine chemokine CCR1 antagonist with a corticosteroid, and their use for the treatment of asthma and chronic obstructive pulmonary disease. ii) Processes for the preparation of a spirocyclic piperidine derivative, a chemokine CCR1 antagonist. These applications point to the preferred compound being a development compound. The evidence for this compound being AZD-4818, a chemokine CCR1 antagonist that was in Phase II development for the treatment of chronic obstructive pulmonary disease, is reviewed in the light of these and earlier patents relating to it.
- 1 May 2007
- Vol. 10 (5) , 313-6
Fragments 2007--what has fragment-based drug discovery delivered for medicinal chemistry? 7 March 2007, Cambridge, UK.
- 1 May 2007
- Vol. 10 (5) , 313-6
Fragments 2007--what has fragment-based drug discovery delivered for medicinal chemistry? 7 March 2007, Cambridge, UK.
- 1 February 2007
- Vol. 10 (2) , 102-5
Nociception: Taking the Pain out of Drug Discovery. 28 November 2006, London, UK.
- 1 February 2007
- Vol. 10 (2) , 102-5
Nociception: Taking the Pain out of Drug Discovery. 28 November 2006, London, UK.